United Therapeutics Corporation (UTHR): Price and Financial Metrics
United Therapeutics Corporation (UTHR)
Today's Latest Price: $135.54 USD
Updated Nov 27 1:00pm
Add UTHR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
UTHR Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.37 for UNITED THERAPEUTICS Corp; that's greater than it is for just 19.03% of US stocks.
- With a year-over-year growth in debt of -20%, UNITED THERAPEUTICS Corp's debt growth rate surpasses only 15.09% of about US stocks.
- In terms of twelve month growth in earnings before interest and taxes, UNITED THERAPEUTICS Corp is reporting a growth rate of -703.98%; that's higher than only 2.82% of US stocks.
- If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be ZNGA, EXK, HLIT, GEOS, and GIGA.
- Visit UTHR's SEC page to see the company's official filings. To visit the company's web site, go to www.unither.com.
UTHR Stock Price Chart Interactive Chart >
UTHR Price/Volume Stats
| Current price | $135.54 | 52-week high | $144.26 |
| Prev. close | $135.07 | 52-week low | $75.58 |
| Day low | $134.29 | Volume | 113,200 |
| Day high | $135.85 | Avg. volume | 509,672 |
| 50-day MA | $121.04 | Dividend yield | N/A |
| 200-day MA | $111.67 | Market Cap | 6.02B |
United Therapeutics Corporation (UTHR) Company Bio
United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.
UTHR Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $135.54 | $244.19 | 80% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for UNITED THERAPEUTICS Corp. To summarize, we found that UNITED THERAPEUTICS Corp ranked in the 60th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 80.5% on a DCF basis. The most interesting components of our discounted cash flow analysis for UNITED THERAPEUTICS Corp ended up being:
- As a business, UTHR is generating more cash flow than 73.69% of positive cash flow stocks in the Healthcare.
- UTHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 31.8% of tickers in our DCF set.
- UNITED THERAPEUTICS Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 21.66. This coverage rate is greater than that of 87.71% of stocks we're observing for the purpose of forecasting via discounted cash flows.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 76% |
| 1% | 78% |
| 2% | 80% |
| 3% | 81% |
| 4% | 83% |
| 5% | 85% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as UTHR, try ANIP, LH, HCSG, DGX, and PBH.
Loading social stream, please wait...